Next Biomedical Co.,Ltd. (KOSDAQ:389650)
South Korea flag South Korea · Delayed Price · Currency is KRW
34,350
-2,700 (-7.29%)
At close: Jul 28, 2026

Next Biomedical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-36.36-311.082,860-7,522-5,732-16,645
Depreciation & Amortization
531.38518.51492.36467.32463.41433.53
Loss (Gain) From Sale of Assets
-9.81-9.81-4.24--5.29-69.58
Asset Writedown & Restructuring Costs
----38.720.8
Loss (Gain) From Sale of Investments
-279.0877.07-113.58-133.56102.4865.86
Stock-Based Compensation
1,7161,1882,1071,486310.27324.19
Other Operating Activities
259.65350.13-6,0052,492-924.4110,046
Change in Accounts Receivable
-953.33-430.04-876.88-617.38-199.44-14.62
Change in Inventory
-283.61-426.83-366.66-228.8-626.88660.13
Change in Accounts Payable
-67.5334.32-44.7813.1440.91-5.08
Change in Other Net Operating Assets
-519.14260.33752.12-117.41-1,676-192.62
Operating Cash Flow
358.21,250-1,201-4,160-8,208-5,396
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,071-3,152-439.39-64.54-195.07-704.65
Sale of Property, Plant & Equipment
35.3721.314.27-19.47380
Sale (Purchase) of Intangibles
------69.59
Investment in Securities
2,2135,242-25,6264,171-10,785-714.73
Other Investing Activities
-105.32-427.32-299.430.0116.1613.72
Investing Cash Flow
-927.881,684-26,3614,106-10,945-1,095

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-----2,400
Long-Term Debt Issued
-1,080369931500-
Total Debt Issued
1,0801,0803699315002,400
Short-Term Debt Repaid
--3,440----1,230
Long-Term Debt Repaid
--971.14-939.53-441.66-451.4-439.48
Total Debt Repaid
-4,549-4,411-939.53-441.66-451.4-1,669
Net Debt Issued (Repaid)
-3,469-3,331-570.53489.3448.6730.52
Issuance of Common Stock
2,1912,23628,920484.2946.56-
Other Financing Activities
---0-0-0-0
Financing Cash Flow
-1,278-1,09528,349973.6395.1721,728

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
42.6-0.35260.79-31.7455.2639.87
Miscellaneous Cash Flow Adjustments
0-----
Net Cash Flow
-1,8051,8391,048888.07-19,00215,276

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-2,713-1,902-1,640-4,225-8,403-6,101
Free Cash Flow Growth
------
Free Cash Flow Margin
-16.13%-11.54%-17.18%-86.53%-300.65%-269.08%
Free Cash Flow Per Share
-332.63-233.95-227.68-672.87-1353.18-1260.87
Levered Free Cash Flow
-5,208-4,293-3,155-3,756-6,103-31,008
Unlevered Free Cash Flow
-5,011-4,063-2,830-3,397-5,877-30,125

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
317.31486.43524.36572.14354.01241.79
Cash Income Tax Paid
---63.92-1.7615.73
Change in Working Capital
-1,824-562.22-536.21-950.45-2,462447.81